Avadel Pharmaceuticals PLC reports results for the quarter ended March 31 - Earnings Summary

Avadel Pharmaceuticals

07/05/2025 14:32

Avadel Pharmaceuticals PLC AVDL.OQ reported a quarterly adjusted loss of 5 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -30 cents.  The mean expectation of ten analysts for the quarter was for a loss of 7 cents per share. Wall Street expected results to range from -14 cents to -2 cents per share.

Revenue rose 93.2% to $52.51 million from a year ago; analysts expected $50.71 million.

Avadel Pharmaceuticals PLC's reported EPS for the quarter was a loss of 5 cents​.

The company reported a quarterly loss of $4.92 million.

Avadel Pharmaceuticals PLC shares had risen by 10.3% this quarter and lost 17.8% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had fallen by about 25% in the last three months.​

In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Avadel Pharmaceuticals PLC is $18.00

This summary was machine generated from LSEG data May 7 at 01:32 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
-0.07
-0.05
Beat
Dec. 31 2024
-0.04
-0.05
Missed
Sep. 30 2024
-0.06
-0.03
Beat
Jun. 30 2024
-0.16
-0.14
Beat